Biotech

All Articles

Amgen documents first stage 3 gain for $400M chronic eczema medication

.Amgen has actually shared (PDF) the very first phase 3 data on its own $400 thousand eczema drug, c...

Biogen, UCB file phase 3 lupus succeed after falling short earlier trial

.Biogen and also UCB's gamble on advancing into stage 3 on the back of a broken research study hopes...

Aptadir wishes brand new RNA preventions may reverse complicated cancers

.Italian biotech Aptadir Therapies has actually introduced with the pledge that its pipe of preclini...

Wave surfs DMD success to regulatory authorities' doors, sending stockpile

.Surge Life Sciences has actually fulfilled its own target in a Duchenne muscle dystrophy (DMD) stud...

Sanofi tweezes new CSO from in-stealth biotech

.After a handful of years in biotech, Mike Quigley, Ph.D., is going back to the pharma crease, takin...

Achilles trickles tissue treatment program, bandages for discharges after missing out on 'office stability' targets

.Achilles Therapies has wrecked its technique. The English biotech is quiting working on its clinica...

Aligos advertises phase 2 MASH succeed, reducing liver fat approximately 46%

.Aligos Therapeutics is heralding a midstage gain in metabolic-dysfunction linked steatohepatitis (M...

Basilea ratings $268M BARDA backing for antifungals, anti-biotics

.Basilea Pharmaceutica's job creating brand new antifungals has acquired a notable boost from the un...

Capricor sells Europe civil liberties to late-stage DMD treatment for $35M

.Having currently scooped up the U.S. civil liberties to Capricor Rehabs' late-stage Duchenne muscle...

FDA scraps adcomm for Applied's uncommon ailment medicine

.After pushing back the decision date for Applied Therapies' metabolic problem drug govorestat, the ...